Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Gastroenterol Hepatol ; 17(10): 1047-52, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16148549

ABSTRACT

OBJECTIVE: To quantify the impact of infliximab therapy on health care resource utilization in the UK. METHODS: A retrospective audit was undertaken at seven centres in the UK, which reviewed patient notes for a period of 6 months before and 6 months after an initial infliximab infusion. Details of hospital admissions, outpatient visits, operations, diagnostic procedures, drug usage, and overall efficacy were collected. Results were compared for the two 6 month study periods. RESULTS: A total of 205 patients (62% female, median age 33 years) with moderate/severe Crohn's disease were audited. The majority of patients had chronic active disease (62%) and most received one infusion initially (72%). Clinicians rated 74% of responses as good to excellent and patients 72%. Most patients had concomitant immunosuppression (pre: 75%, post: 75%). Approximately half of the patients (45%) stopped taking steroids, with a further 34% having a dosage reduction. A fall of 1093 inpatient days was seen (1435 vs. 342) in the 6 months following infliximab administration. There were seven fewer operations, 33 fewer examinations under anaesthetic, and 99 fewer diagnostic procedures. Outpatient visits were similar pre- versus post- (555 vs. 534). The total reduction in direct costs amounted to an estimated pounds 591,006. Three hundred and fifty-three infliximab infusions were administered at an estimated cost of pounds 562,719. Thus, there was a net reduction of pounds 28,287 or pounds 137.98 per patient. CONCLUSIONS: Infliximab appears to be a potentially cost effective treatment for selected patients based on the reduced number of inpatient stays, examinations under anaesthetic, and diagnostic procedures over a 6 month period.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Crohn Disease/drug therapy , Health Resources/statistics & numerical data , Adolescent , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/economics , Antirheumatic Agents/economics , Cost-Benefit Analysis , Crohn Disease/economics , Crohn Disease/surgery , Drug Costs/statistics & numerical data , Epidemiologic Methods , Female , Health Care Costs/statistics & numerical data , Health Services Research , Hospitalization/statistics & numerical data , Humans , Infliximab , Male , Middle Aged , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors , United Kingdom
2.
J Gambl Stud ; 21(2): 133-55, 2005.
Article in English | MEDLINE | ID: mdl-15870984

ABSTRACT

Although prevalence studies consistently indicate that many thousands of Australians experience gambling-related problems, only a relatively small proportion of these people seek professional help. This study examines the principal motivations for, and impediments to, help-seeking in a sample of 77 problem gamblers recruited from agencies and the general community. The results indicated that profession help-seeking is predominantly crisis-driven rather than being motived by a gradual recognition of problematic behaviour. Shame, denial and social factors were identified as the most significant barriers to change rather than a lack of knowledge, or dislike of, treatment agencies. The value of early interventions including the screening of gamblers in routine medical consultations and partner support strategies is discussed.


Subject(s)
Behavior, Addictive/psychology , Gambling/psychology , Intention , Patient Acceptance of Health Care/psychology , Self Efficacy , Adult , Female , Humans , Male , Middle Aged , Social Environment , South Australia , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL
...